ALX Oncology Exchanges 13.35M Shares for Pre-Funded Warrants with Blackstone, RA Capital, venBio

summarizeSummary

ALX Oncology exchanged 13.35M shares held by Blackstone, RA Capital, and venBio for pre-funded warrants exercisable at $0.001 per share, a non-cash restructuring that preserves the holders' economic exposure while creating future share issuance overhang.

check_boxKey Events · Financing and Capital Events · ALXO

• 13.35M Shares Exchanged for Pre-Funded Warrants

  Three institutional holders surrendered 13,353,384 shares for no consideration and received pre-funded warrants to purchase the same number of shares at $0.001 per share.

• Blackstone, RA Capital, venBio Participate

  Blackstone Annex Master Fund exchanged 12,885,891 shares, RA Capital Healthcare Fund 213,667 shares, and venBio Global Strategic Fund 253,826 shares.

• Non-Cash Restructuring, No New Capital

  The exchange was executed under Section 3(a)(9) and raises no new cash; it converts existing common stock into derivative instruments exercisable at essentially zero cost.

• Ownership Blockers Limit Immediate Overhang

  Pre-funded warrants carry 4.99%/9.99% beneficial ownership caps, preventing any holder from crossing those thresholds without 61 days' notice.

auto_awesomeAnalysis · ALXO · Life Sciences

ALX Oncology restructured 13,353,384 shares held by three institutional investors into pre-funded warrants exercisable at $0.001 per share. The exchange is non-cash and does not raise new capital, but it converts existing common stock into a derivative instrument that can be exercised at essentially no cost. The practical effect is that these holders retain full economic exposure while gaining flexibility on timing and tax treatment of any future sales. The 4.99%/9.99% ownership blockers prevent any single holder from crossing those thresholds without notice, which limits the immediate overhang from forced selling. For a company that reported $153.4M in cash as of Q2 2026, this is a balance-sheet-neutral restructuring rather than a capital raise, but it does create a future share issuance overhang if and when the warrants are exercised.